UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,000 06/09/2006 Xiaorong You		ES-4676-957	6123	
	7590 11/17/201 erhye PC / DSM Desote	EXAMINER		
11th Floor, 901	North Glebe Road	REDDICK, MARIE L		
Arlington, VA	22203	ART UNIT	PAPER NUMBER	
		1762		
			MAIL DATE	DELIVERY MODE
			11/17/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	on No.	Applicant(s)					
Office Action Summary			10/565,00	00	YOU, XIAORONG				
			Examiner		Art Unit				
		MARIE RE		1762					
Peri	od fo	The MAILING DATE of this communication ap or Reply	pears on the	cover sheet with the c	orrespondence ad	ldress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
	1)	Responsive to communication(s) filed on <u>24 May 2011 and 09 September 2011</u> .							
	a) 🔲		s action is n		•				
		<i>'</i> —			set forth during the	e interview on			
•	ا لر	An election was made by the applicant in response to a restriction requirement set forth during the interview on; the restriction requirement and election have been incorporated into this action.							
	4)								
	·/ _	closed in accordance with the practice under	•	·					
		The product and the product and the	en parto da	ay, 0, 1000 0.5. 11, 10	0.0.2.0.				
Disposition of Claims									
į	5)🛛	Claim(s) <u>1-5,13-17 and 21-26</u> is/are pending i	n the applic	ation.					
		5a) Of the above claim(s) is/are withdrawn from consideration.							
(6)	Claim(s) is/are allowed.							
-	7) 🛛	☑ Claim(s) <u>1-5,13-17 and 21-26</u> is/are rejected.							
8	8)	Claim(s) is/are objected to.							
Ç	9) Claim(s) are subject to restriction and/or election requirement.								
Арр	licat	ion Papers							
1:	0) 🖂	The specification is objected to by the Examine	er.						
	11) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
1:	12) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119									
	_	•	a priprity up	Nor 25 11 C C & 110(a)	(d) or (f)				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) All b) Some * c) None of:									
1. Certified copies of the priority documents have been received.									
2. Capies of the priority documents have been received in Application No									
3. Copies of the certified copies of the priority documents have been received in this National Stage									
application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.									
Attachment(s)									
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)									
2) 🗔		ce of Draftsperson's Patent Drawing Review (PTO-948)		Paper No(s)/Mail Da 5) Notice of Informal Pa					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 05/24/11. 5) Notice of Informal Patent Application Other:									

Application/Control Number: 10/565,000 Page 2

Art Unit: 1762

DETAILED ACTION

Information Disclosure Statement

 The information disclosure statement filed O5/24/11 has been considered by the Examiner.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 4. Claims 1-5, 13-17 and 21-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Melisaris et al (US 6,099,787) in combination with Gummeson (US 2002/0198289).

Melisaris et al teach radiation curable compositions defined basically as containing i) at least one radiation curable component, ii) a filler, iii) at least one photoinitiator, iv) a thixotropic agent, v) a flow-control agent, and vi) other conventional additives wherein, the at least one radiation curable component includes 70-95 % by weight of cationically curable compounds (epoxy compounds such as 3, 4-epoxycyclohexanecarboxylate, epoxy resins which include homopolymers and

Art Unit: 1762

copolymers of polyacrylate and polymethacrylate glycidyl esters and mixtures thereof) and 1-30 % by weight of free-radically curable compounds which include mono-, diand poly(meth)acrylates having functionality up to 9, the filler, in an amount of from about 2-90 % by weight, includes untreated and treated silica compounds, the at least one photoinitiator includes a cationic photoinitiator and a free-radical initiator, the thixotropic agent includes Aerosil R-972 (fumed silica) and the other conventional additives, in an amount up to 20 % by weight, include stabilizers, pigments, wetting agents, surfactants, flow control agents, dyes, etc. (Abstract, col. 1, lines 8-18, cols. 3-7, cols. 9-19, the Runs, TABLES 1 and 2 and claims of Melisaris et al and claims 1-5, 13-17 and 21-26).

Melisaris et al differ basically from the claimed invention as per the non-express disclosure of an embodiment directed to the specifically defined flow aid selected from the group consisting of a polyalkyleneoxide-modified polydimethylsiloxane and an ethyl acrylate-2-ethylhexyl acrylate copolymer (claims 1, 2 and 16).

Gummeson teaches UV curable compositions, similar to the radiation curable compositions of Melisaris et al, defined basically as containing a water/organic solvent carrier medium, a colorant, a UV curable resin, a photoinitiator and other conventional additives wherein the UV curable resins include epoxy and urethane resins, the colorant includes anionic or cationic dyes or pigments with or without a dispersing agent and the other conventional additives include penetrants, humectants, polymeric chemical additives such as polyvinylpyrrolidinone, biocides, surfactants such as Silwet L-7607 (a polyalkyleneoxide-modified polydimethylsiloxane), etc. (Abstract, paragraphs [0020]-[0079], [0090]-[0105], Runs inclusive, and the claims of Gummeson).

Therefore, one having ordinary skill in the art, at the time of the invention, would have found it obvious to modify the radiation curable composition of Melisaris et al by adding the conventionally well known surfactant taught by Gummeson to the radiation curable composition of Melisaris et al and with a reasonable expectation of obtaining the expected additive effect, absent some evidence of unusual or unexpected results. **COMBINING EQUIVALENTS KNOWN FOR THE SAME PURPOSE:** "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. [T]he idea of combining them flows logically from their having been individually taught in the prior art" (In re Kerkhoven,

While Gummeson does not recognize the polyalkyleneoxide-modified polydimethylsiloxane (Silwet L-7607) as a flow aid, a new use for an otherwise old or obvious compound/composition cannot render a claim to the composition patentable (In re Zierden, 162 USPQ 102 (CCPA 1969)).

626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980)).

As to the specifically defined compositional components, in terms of content (claim 16), one having ordinary skill in the art, at the time of the invention, would have found it obvious to modify Melisaris et al by optimizing the radiation curable composition of Melisaris et al, in terms of content of compositional components as suggested (col. 9, lines 66-67, col. 10, lines 1-2, col. 11, lines 45-55, col. 12, lines 56-67 and TABLES 1 & 2 and the claims of Melisaris et al), such involving only routine experimentation, without undue burden and with a reasonable expectation of success. **Optimization Within**

Prior Art Conditions or Through Routine Experimentation: Generally,

Art Unit: 1762

differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

As to the "viscosity reducible" limitation, the Examiner has a reasonable basis for believing that this limitation may be met by the composition of Melisaris et al since the radiation curable composition of Melisaris et al, as modified, is essentially the same as the claimed viscosity reducible radiation curable composition. It is further believed that the "viscosity", "filler settling speed", and "thixotropic index" limitations, if not taught, may very well be met by the radiation curable composition of Melisaris et al since the composition of Melisaris et al, as modified, is essentially the same as the claimed composition and in the absence of the USPTO having at its disposal the tools and facilities deemed necessary to make physical determinations of this sort. **ONCE A** REFERENCE TEACHING PRODUCT APPEARING TO BE SUBSTANTIALLY IDENTICAL IS MADE THE BASIS OF A REJECTION, AND THE EXAMINER PRESENTS EVIDENCE OR REASONING TENDING TO SHOW INHERENCY, THE BURDEN \$HIFT\$ TO THE APPLICANT TO \$HOW AN UNOBVIOUS **DIFFERENCE:** "[T]he PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on inherency' under 35 U.S.C. 102, on prima facie obviousness' under 35 U.S.C. 103, jointly or alternatively, the burden of

Application/Control Number: 10/565,000

Art Unit: 1762

proof is the same." The burden of proof is similar to that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (quoting In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433-34 (CCPA 1977)).

Page 6

Response to Arguments

- 5. Applicant's arguments, see pages 11-13, filed 09/09/11, with respect to the Claim Objections (1, 2, 16 and 26), the Rejection of claims 25 and 26 under 35 USC 112, first paragraph and the Rejection of claims 21 and 24-26 under 35 USC 112, 2nd paragraph have been fully considered and are persuasive. These issues have been resolved and therefore have been withdrawn.
- 6. The indicated allowability of claims 1-5, 13-17 and 21-26 is herein regrettably rescinded in view of the newly discovered reference(s) to Gummeson (US 2002/0198289) cited by Applicant in the IDS of 05/24/11. The rejection based on the newly cited reference(s) is as set forth supra.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARIE REDDICK whose telephone number is (571)272-5816. The examiner can normally be reached on Mon. - Fri. 7:30 am to 4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, WU DAVID can be reached on (571) 272-1114. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/565,000

Art Unit: 1762

Information regarding the status of an application may be obtained from the Patent

Page 7

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status information for

unpublished applications is available through Private PAIR only. For more information about

the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the

Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If

you would like assistance from a USPTO Customer Service Representative or access to the

automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Marie Reddick
Patent Examiner

Art Unit 1762

/MR/

11/15/11

/DAVID W WU/

Supervisory Patent Examiner, Art Unit 1762